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Abstract
Background: Neural tube defects (NTDs) are common and severe congenital malformations. Pax3 is an essential
gene for neural tube closure in mice but it is unknown whether altered expression or methylation of PAX3
contributes to human NTDs. We examined the potential role of hypermethylation of Pax3 in the development of
NTDs by analyzing human NTD cases and a mouse model in which NTDs were induced by benzo[a]pyrene (BaP), a
widely studied polycyclic aromatic hydrocarbon (PAH).
Methods: We extracted methylation information of PAX3 in neural tissues from array data of ten NTD cases and
eight non-malformed controls. A validation study was then performed in a larger independent population
comprising 73 NTD cases and 29 controls. Finally, we examined methylation patterns and expression of Pax3 in
neural tissues from mouse embryos of dams exposed to BaP or BaP and vitamin E.
Results: Seven CpG sites in PAX3 were hypermethylated in NTD fetuses as compared to controls in the array data.
In the validation phase, significantly higher methylation levels in the body region of PAX3 were observed in NTD
cases than in controls (P = 0.003). And mean methylation intensity in the body region of PAX3 in fetal neural tissues
was positively correlated with median concentrations of PAH in maternal serum. In the mouse model, BaP-induced
NTDs were associated with hypermethylation of specific CpG sites within both the promoter and body region of
Pax3. Supplementation with vitamin E via chow decreased the rate of NTDs, partly recovered the repressed total
antioxidant capacity in mouse embryos exposed to BaP, and this was accompanied by the normalization of Pax3
methylation level and gene expression.
Conclusion: Hypermethylation of Pax3 may play a role in the development of NTDs; DNA methylation aberration
may be caused by exposure to BaP, with possible involvement of oxidative stress.
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Background
Neural tube defects (NTDs) arise from a failed or disor-
dered closure of the neural tube during embryogenesis.
The occurrence of NTDs is around 0.5–2/1000 pregnan-
cies worldwide [1]. Fetuses affected with an NTD are
often stillborn (e.g., anencepahlics), and most surviving
infants suffer from life-long disabilities. The etiology of
NTDs is complex, involving both genetic and
non-genetic factors [2]. Over 300 genes have been iden-
tified to be involved in the regulation of neural tube
closure in mouse NTD mutants [3, 4]; however, only a
few of these genes have successfully been validated in
human NTDs. In addition to potential additive effects of
multiple risk alleles, increasing attention has also fo-
cused on the potential for epigenetic alterations to con-
tribute to the occurrence of NTDs by mediating the
interplay of fetal genetics and environmental factors [5].
Epigenetic modification can cause changes in gene ex-
pression that are not directly related to the DNA se-
quence itself, of which DNA methylation is one of the
best understood epigenetic mechanisms [6]. During early
development, a tight regulation of genome-wide erasure
of epigenetic footprints with resetting of the methylation
signature takes place, making developing fetuses particu-
larly susceptible to epigenetic dysregulation as a conse-
quence of environmental exposure [7, 8]. Abnormal
genome-wide methylation during embryogenesis has
been linked to developmental abnormalities at birth, in-
cluding NTDs. Recent studies have demonstrated that
global DNA hypomethylation, evaluated using LINE-1
methylation as an indicator in human fetuses, was asso-
ciated with an increased risk for NTDs [9]. Aberrations
of methylation at specific genes are reported to be in-
volved in NTDs, including imprinted genes [10, 11],
DNA repair genes [12], planar-cell polarity genes [13,
14], and HOX genes [15].
Pax3 is a paired-homeodomain-containing transcrip-
tion factor essential for promoting neural crest induc-
tion, maintenance, migration, and differentiation [16].
Previous studies in mice have shown that Pax3 function
is required for neural tube closure. Several alleles of
Pax3 cause NTDs in mice and homozygous Splotch
(Sp2H) embryos develop NTDs with 100% penetrance
[17]. However, the role of PAX3 in human NTDs re-
mains unclear. Recessive and dominant mutations in
PAX3 in humans are known to cause Waardenburg syn-
drome, an autosomal dominant condition that affects
neural crest-derived structures and also includes spina
bifida as part of its phenotypic spectrum [18]. A 5-bp
deletion in exon 5 of the PAX3 gene was reported in a
patient with spina bifida [19]. In contrast, the results
from a case-control study including 74 infants with
spina bifida and 87 non-malformed controls indicated
that variants in PAX3 were not strong risk factors for
human spina bifida [20]. Therefore, exploring mecha-
nisms other than coding sequence variants, such as
methylation modification, in PAX3 may provide novel
insight into the etiology of human NTDs.
We hypothesized that aberrant DNA methylation of
Pax3 plays a role in the formation of NTDs. To test this
hypothesis, we first compared the difference in methyla-
tion levels of CpG sites within PAX3 using genomic
methylation array data with DNA from neural tissues of
NTD cases and non-malformed controls. The methylation
status of the CpG sites that were found to differ was then
validated in a larger NTD case-control population. We
tested whether there was any correlation between CpG
site methylation levels in fetal neural tissues and maternal
serum concentrations of polycyclic aromatic hydrocarbons
(PAHs), a class of ubiquitous environmental pollutants
that have been shown to be associated with the risk for
NTDs in epidemiological studies [21]. Finally, we assessed
the methylation level and gene expression of Pax3 in
neural tissues from mouse embryos exposed in utero to
benzo[a]pyrene (BaP), a widely studied PAH that induces
NTDs [22]. In addition, we assayed markers of oxidative
stress in fetal mice to further explore the possible mecha-
nisms by which BaP might affect methylation regulation.
Results
Methylation of PAX3 gene in genomic microarray
A detailed description on the genome-wide methylation re-
sults obtained from Infinium HumanMethylation450 Bead-
Chip (HM450K), using DNA isolated from neural tissues
from ten NTD cases and eight unrelated non-malformed
controls can be found elsewhere [23]. In brief, out of
485,199 CpG sites across the entire genome, 23,294 (4.8%)
were differentially methylated between cases and controls.
Of the differentially methylated CpG sites, 12,383 (53.2%)
were significantly hypermethylated and 10,911 (46.8%) were
significantly hypomethylated in NTD cases when compared
to controls. The characteristics of the NTD cases and con-
trols in phase 1 are presented in Additional file 1: Table S1.
In the PAX3 gene, the focus of this study, a total of 54
CpG sites were extracted from the HM450K array data,
of which 47 CpG sites (87.0%) were found to be hyper-
methylated. And 7 out of the 47 CpG sites exhibited sta-
tistically greater methylation in NTD fetuses than in
controls (Additional file 2: Table S2). Analysis of the
genomic location of the seven significantly hypermethy-
lated CpG sites showed that one CpG was located at
TSS1500, one in the 5′UTR, and the remaining five
CpGs were within the body of the gene (Fig. 1a).
Validation of PAX3 methylation in an independent cohort
of NTD cases and controls
In order to validate these findings, 73 NTD cases and 29
controls were used to examine the differentially
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methylated regions of PAX3 identified in phase 1 using
Sequenom EpiTYPER. The demographic characteristics
of the subjects are described in Table 1. Three DNA
amplicons were developed that cover 35 CpGs (Fig. 1a).
In the present study, TSS1500, TSS200, 5′UTR, and the
1st exon were defined as the promoter region of PAX3
gene. As shown in Fig. 2a, no significant difference in
overall mean methylation levels in the promoter region
of PAX3 was observed between NTD cases and controls.
However, NTD samples exhibited significantly higher
DNA methylation levels (13.9 ± 10.1%) than control sam-
ples (7.8 ± 4.2%) in the gene body region (P = 0.003)
(Fig. 2b). Furthermore, within the gene body, all CpG
sites except CpG_12 showed significantly higher levels
of methylation in the NTD samples compared to con-
trols (Fig. 2e). After Benjanmini-Hochberg correction,
methylation levels in five of the nine CpG sites were still
significantly higher in NTD cases.
The relationship between hypermethylation of PAX3
and the risk of NTDs was examined. Methylation levels
were categorized according to the median methylation
level of the controls. As shown in Table 2, a higher level
of methylation in the gene body region was associated
with 6.24-fold increased risk for NTDs (95% CI 1.30–
29.97).
Correlation between PAH concentrations in maternal
serum and PAX3 methylation in fetal neural tissues
A previous study from our team found that higher PAH
concentrations in maternal serum were associated with
an increased risk for NTDs [24]. We therefore con-
ducted a correlation analysis between PAH concentra-
tions in maternal serum and PAX3 methylation levels
in fetal neural tissues (N = 51 mother-fetus pairs) to
further our understanding of the potential relationship
of PAH exposure, gene methylation, and NTDs risk.
Notably, a significant positive correlation was found be-
tween mean methylation levels in the PAX3 gene body
and median concentrations of high-molecular-weight
PAHs in maternal serum (r = 0.310. P = 0.027)
(Additional file 3: Table S3).
Disturbed methylation of Pax3 in mouse embryos
exposed to BaP
We further investigated the finding of a correlation be-
tween maternal serum PAH concentrations and PAX3
hypermethylation in humans by utilizing a BaP-induced
NTD mouse model. Three amplicons developed accord-
ing to the mouse genome were used (Fig. 1b). The body
region of Pax3 showed a trend toward higher levels of
methylation in the BaP-treated group compared with
controls (Fig. 3a), but this did not reach statistical sig-
nificance. Furthermore, in terms of specific CpG sites,
two significantly hypermethylated CpG sites within the
promoter and two within the body region of Pax3 were
respectively detected in the BaP-exposed mouse fetuses
when compared to the non-exposed fetuses (Fig. 3b–d).
The role of oxidative stress in BaP-related disturbed Pax3
methylation and expression
Since BaP exposure was hypothesized to favor the gener-
ation of reactive oxygen species (ROS) in the embryos,
we inferred that oxidative stress may get involved in the
aberrant Pax3 methylation induced by BaP. As shown in
Fig. 4, compared to the control group, the levels of total
antioxidant capacity (TAC) and the activity of super-
oxide dismutases (SODs) were decreased. Real-time PCR
and whole mount in situ hybridization showed that BaP
exposure significantly decreased the transcription of
Pax3 (P = 0.008) (Fig. 5). After co-supplemented with
vitamin E, a commonly used antioxidant, the repressed
levels of TAC and SODs were partly restored (Fig. 4).
Coincidentally, the hypermethylation of Pax3 in specific
CpG sites induced by BaP treatment was recovered and
Pax3 expression was also normalized by vitamin E sup-
plementation (Figs. 3 and 5), which suggested a causal
effect of oxidative stress on both Pax3 methylation and
expression.
Discussion
Pax3 is a key gene, encoding a transcription factor re-
quired for neural tube closure [17]. In this study, we
evaluated the methylation status of PAX3 in a two-phase
(See figure on previous page.)
Fig. 1 Schematic diagram showing the location of PAX3 region analyzed. a Locations of the CpG sites detected in phase 1 and phase 2 of
human methylation analysis. The differentially methylated CpG units identified by HM450K were indicated as white dots that above the black line
(cg19352038, cg08022524, cg04407305, cg25809290, cg23077820, cg11490745, and cg04134754). In phase 2, three DNA amplicons were
developed to validate the differentially methylated region detected in phase 1; amplicon 1 covered 10 analytical CpG sites located in the TSS1500
region of PAX3; amplicon 2 covered 16 analytical CpG sites located between TSS200 and 5′UTR region; amplicon 3 covered 9 analytical CpG sites
located between the 4th and 5th exon. All the CpG sites detected in replication phase were indicated as black dots under the line. b Locations of
the Pax3 CpG sites detected in mouse methylation analysis. Three DNA amplicons were developed as in human study. Amplicon 1 covered 8
analytical CpG sites located in the TSS1500 region of Pax3; amplicon 2 covered 7 analytical CpG sites which located between TSS200 and 5′UTR
region; amplicon 3 covered 12 analytical CpG sites located between the 4th and 5th exon. c Schematic diagram of interest indicating putative
transcription factor-binding sties in amplicon 3 of human PAX3 gene in intron 4. CpG sites predicted by JASPAR (predictive value > 8) to bind
transcription factors are described under the sequence. CpG site 3 was the same as cg23077820 identified differentially by HM450K in phase 1. All
the CpG sites except CpG site 12 were differentially methylated between NTDs and controls by Sequenom EpiTYPER in phase 2
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design study to examine whether there is a potential role
of PAX3 methylation in the development of human
NTDs. Differentially hypermethylated CpG sites were
found in the promoter and gene body region within
PAX3 in the neural tissues of NTD cases. Association
analysis showed that a higher methylation level in the
gene body region was associated with an elevated risk
for NTDs. Moreover, PAH concentrations in maternal
serum, which were known to be associated with in-
creased risk of NTDs, were positively correlated to
methylation levels at several CpG sites. In the
BaP-induced NTD mouse model, hypermethylation of
Pax3 gene and suppressed gene expression were ob-
served in embryos with BaP treatment, along with re-
duced TAC level. We previously showed that vitamin E
supplementation could decrease the rate of NTDs and
alleviate oxidative stress in BaP exposed embryos [22].
Here, we further demonstrated that vitamin E mitigated
the shifts in Pax3 methylation and gene expression.
Studies on the role of the Pax3 in NTDs have mostly
focused on gene depletion or loss of function mutants
[17]. In mice, mutations in Pax3 give rise to the Splotch
(Sp) phenotype, which includes exencephaly, spina
bifida, and neural crest abnormalities in homozygous
mutant embryos [25, 26]. The human PAX3 gene ex-
hibits high homology with mouse Pax3. Mutations
within the human PAX3 gene have been found in Waar-
denburg syndromes, a condition which is occasionally
associated with NTDs [18]. A previous study identified
two spina bifida patients who had small interstitial
chromosomal deletions involving PAX3 [27]. Exon se-
quencing of PAX3 in 114 cases with spina bifida also
identified two common variants; however, without un-
affected individuals, the influence of these variants on
the risk of spina bifida could not be determined [28]. To
the contrary, the screening results from 74 spina bifida
cases and 87 control infants suggested that variant in
PAX3 was not a major contributor to the overall burden
of NTDs at population level [20]. Recently, evidence
from animal studies suggested that aberrant methylation
of Pax3 was involved in the development of NTDs in-
duced by hyperglycemia [29, 30]. However, to date, no
study investigating the role of PAX3 methylation in the
etiology of human NTDs has been reported. In our
study, we analyzed the methylation status of PAX3 gene
in neural tissues from human fetuses, and our results
showed that the methylation level in PAX3 was signifi-
cantly higher in NTD cases than in non-malformed
controls.
Unexpectedly, in our study, compared with promoter
region, the body region of PAX3 was more consistently
hypermethylated in NTD cases and the differentially
methylated region was mainly located in intron 4. Our
results imply that a methylation change in the body
Table 1 Characteristics of NTD cases and controls in phase 2 for
methylation assay
Characteristic Control (N = 29)a Case (N = 73)a P valueb
Maternal age (years) 0.703
< 25 14 (50.0) 30 (41.1)
25–29 6 (21.4) 20 (27.4)
≥ 30 8 (28.6) 23 (31.5)
BMI (kg/m2) 0.595
< 18.5 2 (6.9) 6 (8.6)
18.5–27.9 22 (75.9) 57 (81.4)
≥ 28 5 (17.2) 7 (10.0)
Maternal education 0.005
Primary or lower 4 (13.8) 9 (12.5)
Junior high 12 (41.4) 52 (72.2)
High school or above 13 (44.8) 11 (15.3)
Occupation < 0.001
Farmer 14 (48.3) 61 (87.1)
Non-farmer 15 (51.7) 9 (12.9)
Previous birth defects history 0.200
Yes 0 4 (5.6)
No 28 (100) 67 (94.4)
Gravidity 0.219
1 17 (58.6) 32 (45.1)
≥ 2 12 (41.4) 39 (54.9)
Parity 0.060
1 18 (72.0) 32 (50.0)
≥ 2 7 (28.0) 32 (50.0)
Periconceptional folic acid supplementation < 0.001
Yes 4 (14.3) 42 (60.0)
No 24 (85.7) 28 (40.0)
Cold or fever 0.059
Yes 5 (17.9) 27 (37.5)
No 23 (82.1) 45 (62.5)
Active or passive smoking 0.210
Yes 15 (55.6) 29 (41.4)
No 12 (44.4) 41 (58.6)
Drinking 0.940
Yes 17 (65.4) 47 (66.2)
No 9 (34.6) 24 (33.8)
Gestational age (weeks) 0.023
< 28 14 (48.3) 52 (72.2)
28–36 7 (24.1) 14 (19.4)
> 36 8 (27.6) 6 (8.3)
Fetal sex 0.129
Male 17 (58.6) 28 (41.8)
Female 12 (41.4) 39 (58.2)
aData were presented in number (percentage). Total number may not be
equal to the total of cases or controls due to missing or unknown data
bCases and controls were compared by Pearson’s χ2 test, or Fisher’s exact test
if any cell expectation was less than 5
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region of PAX3 may be an epigenetic component of hu-
man NTDs, which is reminiscent with findings for the
HOXB7 gene in a myelomeningocele (spina bifida)
case-control study [15]. In the latter study, a
genome-wide methylation assay found three CpGs in
HOXB7 gene body to be hypomethylated in myelome-
ningocele patients when compared to controls, and
these were further verified in a larger population,
using the Sequenom EpiTYPER platform. Studies on
GRHL3 and SOX18 also reported that altered methy-
lation within the gene body was associated with the
risk for NTDs [14, 31].
It is generally accepted that DNA methylation changes
in the promoter and gene body regions may have differ-
ential effects on gene expression. DNA methylation in
promoter regions is usually negatively associated with
gene expression, whereas in the gene body, the impact is
not consistent, with both positive and negative impacts
having been reported [32, 33]. In the present study, a
negative correlation between gene body DNA methyla-
tion and transcription level of Pax3 was observed in
mouse embryos, which was in line with the finding in
hyperglycemia-induced NTDs [29]. The underlying
mechanisms of gene body methylation in regulating gene
expression have not been well understood. Recently, in-
creasing evidence demonstrating the role of DNA
methylation in alternative splicing regulation has been
reported, which is essential for providing tissue-specific
features for some genes [34]. DNA methylation is nor-
mally more abundant in exons compared to the flanking
introns, which is a marker for distinguishing exons from
introns. Previous studies proposed that the change of
exon methylation levels would affect the recognition of
exons while splicing [35]. It is thus reasonable to
hypothesize that the methylation status of intron might
also be crucial for alternative splicing. Further, cis-acting
element has been recognized in intron, which could
regulate gene expression [34]. Within intron 4 of PAX3,
a number of transcription factors were predicted to bind
at several CpG sites examined in the present study, with
high predictive values (predictive value > 8, JASPAR,
Fig. 1c), which might be responsible for the observed re-
pressed gene expression. However, more research is ne-
cessary to examine this point in detail.
PAX3 hypermethylation by itself is not likely to be a
sole cause for NTDs but rather be part of a complex
combination of environmental and epigenetic risk fac-
tors. Our previous epidemiological studies have
(See figure on previous page.)
Fig. 2 PAX3 methylation pattern assayed by Sequenom EpiTYPER in NTD cases and controls. a Mean methylation level of PAX3 promoter region
(amplicon 1 and amplicon 2) between NTD cases and controls. b Mean methylation level of PAX3 body region (amplicon 3) between NTD cases
and controls. c–e Methylation levels for each CpG site between NTD cases and controls in promoter (c, d) and body region (e). TSS1500, TSS200,
5′URT, and the 1st exon were defined as the promoter region of PAX3 gene in this study. The significance of differences was calculated using
Independent t-test. *P < 0.05, **P < 0.01, ***P < 0.001, compared with control group. #P < 0.05, compared with control group after
FDR adjustment
Table 2 Risks of NTDs associated with methylation level of PAX3 gene in fetal neural tissues
All NTDs Anencephaly Spina bifida
ORa (95% CI) P value ORa (95% CI) P value ORa (95% CI) P value
Promoter region 0.69 (0.19, 2.45) 0.690 0.68 (0.15, 3.17) 0.683 0.57 (0.11, 2.98) 0.502
Amplicon_1_CpG_1 0.58 (0.17, 2.04) 0.398 0.44 (0.09, 2.18) 0.444 0.41 (0.07, 2.36) 0.414
Amplicon_1_CpG_3.4.5 4.24 (1.14, 15.77) 0.031 3.26 (0.56, 18.85) 0.187 4.22 (0.87, 20.56) 0.075
Amplicon_1_CpG_7 2.49 (0.73, 8.55) 0.146 1.28 (0.26, 6.36) 0.760 5.86 (1.18, 29.10) 0.031
Amplicon_1_CpG_8.9.10 3.11 (0.87, 11.09) 0.080 3.04 (0.48, 19.36) 0.239 6.57 (1.23, 35.11) 0.028
Body region 6.24 (1.30, 29.97) 0.022 4.30 (0.71, 26.25) 0.114 10.76 (1.06, 109.45) 0.045
Amplicon_1_CpG_1.2 2.87 (0.81, 10.17) 0.103 2.34 (0.52, 10.51) 0.266 25.16 (1.57, 404.30) 0.023
Amplicon_1_CpG_3 4.34 (1.12, 16.78) 0.034 4.12 (0.78, 21.89) 0.096 5.15 (0.81, 32.68) 0.082
Amplicon_1_CpG_4.5.6.7 1.42 (0.40, 5.12) 0.588 1.08 (0.25, 4.72) 0.917 3.35 (0.44, 25.28) 0.241
Amplicon_1_CpG_8 0.94 (0.16, 5.54) 0.945 0.40 (0.19, 20.06) 0.997 3.98 (0.19, 82.64) 0.372
Amplicon_1_CpG_10 4.83 (0.99, 23.55) 0.052 2.04 (0.33, 12.65) 0.443 16.95 (1.74, 165.25) 0.015
Amplicon_1_CpG_11 2.19 (0.61, 7.80) 0.227 0.72 (0.13, 3.90) 0.698 5.30 (0.65, 43.29) 0.120
Amplicon_1_CpG_13 3.05 (0.83, 11.15) 0.092 1.08 (0.21, 5.55) 0.930 5.23 (1.00, 27.75) 0.050
Amplicon_1_CpG_14.15 7.52 (1.36, 41.58) 0.021 6.23 (0.86, 45.03) 0.070 6.65 (0.68, 65.51) 0.104
aOR was adjusted by maternal education, occupation, periconceptional folic acid use and fetal sex, gestational age. ORs were in italic when P value < 0.05
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suggested that maternal exposure to PAHs was associ-
ated with an elevated risk of NTDs in the offspring [21,
24]. Cohort studies reported that prenatal PAH exposure
was associated with lower global methylation and hyper-
methylation of interferon γ in umbilical cord white blood
cells [36, 37]. Several toxicological studies have also sug-
gested that BaP exposure could disrupt DNA methyla-
tion status [38, 39]. Importantly, in the present study, we
found that differentially methylated CpG sites in PAX3
gene in fetal neural tissues were positively correlated
with PAH concentrations in maternal serum. In line with
these findings in human subjects, our mouse experiment
showed that the methylation level of Pax3 was elevated
after BaP treatment, indicating that the presence of BaP
impacts Pax3 methylation regulation. These findings
support the hypothesis that hypermethylation of Pax3
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Fig. 3 The effects of BaP and vitamin E on Pax3 methylation in E10.5 mouse embryos. a Mean methylation level of promoter region (amplicon 1
and amplicon 2) and body region (amplicon 3) within Pax3. b–d Methylation level for specific CpG sites in promoter region (b, c) and body
region (d) among control group, BaP-treated group and vitamin E co-supplementation group (n = 24–28). TSS1500, TSS200, 5′URT, and the 1st
exon were defined as the promoter region of Pax3 gene in this study. The significance of differences was calculated using ANOVA. *P < 0.05, **P
< 0.01, ***P < 0.001, compared with control group. VE vitamin E
Fig. 4 The effects of BaP and vitamin E on TAC and SOD activity in E10.5 mouse embryos. Data were expressed as mean ± SD (n = 8–10). *P < 0.05,
**P < 0.01, ***P < 0.001, compared with control group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with vitamin E supplemented group. VE vitamin E
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gene is involved in abnormal closure of neural tube sec-
ondary to PAH exposure.
In considering how BaP exposure could affect methy-
lation, accumulating evidence has demonstrated that
oxidative stress in response to various environmental in-
sults or maternal dietary factors is responsible for aber-
rant DNA methylation [40–43]. In our study,
hypermethylation of Pax3 and repressed gene expres-
sion, along with reduced TAC level, were observed in
BaP-treated mouse embryos. Co-administration with
vitamin E could rescue NTDs induced by BaP, partly
normalized the TAC level, and attenuate the hyperme-
thylation of Pax3 and the repressed gene expression. All
these findings support the postulation that the oxidative
stress may be causally involved in aberrant DNA methy-
lation in the BaP-treated group, which might be the
underlying mechanism for the development of NTDs
caused by BaP. Consistent with this idea, a previous in-
vestigation revealed that epigallocatechin gallate, which
is the major polyphenol in green tea and is believed to
act as an antioxidant, could block hypermethylation of
several neural tube closure essential genes induced by
maternal diabetes, including Pax3 [30]. Although it is
not precisely known, previous investigations proposed
that oxidative stress could influence the synthesis of
S-adenosylmethionine [44], the expression of DNA
methyltransferase [45], and the activity of the ten eleven
translocation enzymes [46], which are all critical for
DNA methylation. On the other hand, epigenetic regula-
tion may also contribute to impairment of antioxidant
gene expression [47]. In this regard, the ROS production
and epigenetic regulation establish an interconnected
cycle, which would amplify external factors toward the
progression of pathological disorders.
DNA methylation is considered tissue-specific and there-
fore appropriate biological samples for methylation study
are crucial. One advantage of our study is that neural tis-
sues from fetuses were used for assessment of methylation,
which makes our methylation study more relevant to the
outcome, as compared to those that used blood DNA as
the surrogate [15]. The limitation is that we did not investi-
gate the expression of PAX3 gene in our human subjects,
as fresh neural tissue samples of terminated NTD cases for
RNA assay are extremely difficult to collect. Although our
mouse experiment may provide a clue, additional studies
are needed to correlate the methylation levels of the PAX3
gene body with PAX3 gene or protein expression values.
Another limitation is that more case mothers reported folic
acid supplementation than control mothers, which might
cause the differences in methylation levels between the two
groups. However, when analyses were performed by folic
acid supplementation status in the case group, no differ-
ences in the methylation level of PAX3 were found between
those with or those without folic acid use (Additional file 4:
Figure S1), suggesting that folic acid has no impact on
methylation level in the present study.
Conclusions
In conclusion, we found that hypermethylation of Pax3
and the downregulation of the gene may be important
A B
Fig. 5 The Effects of BaP and vitamin E on Pax3 gene expression in mouse embryos. a Whole mount in situ hybridization of Pax3 in E9.5
embryos. In control embryos, Pax3 mRNA was detected in the dorsal neural tube and somites as expected, while less gene expression was seen
in the forebrain and midbrain of embryos exposed to BaP. The dashed lines on the whole mount panels indicate the orientation of respective
sections. b Relative quantitative real-time PCR of Pax3 mRNA from E10.5 embryos exposed to BaP and co-supplemented with vitamin E. Values
were normalized against Gapdh and represented as mean ± SE (n = 5–8). *P < 0.05, compared with control group. fb forebrain, mb midbrain, hb
hindbrain, NT neuroepithelium, VE vitamin E
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events in the development of NTDs during embryogen-
esis. A relationship exists between higher maternal
serum PAH concentrations and PAX3 hypermethylation
in fetal neural tissues, which is further supported by our
mouse experiments. In addition, oxidative stress may be
involved in the process of environmental exposure and
methylation modification. Our study provides novel evi-
dence on the interaction between genetic and environ-
mental factors in the etiology of NTDs.
Methods
Study subjects
The human subjects were recruited from rural counties
in Shanxi province of northern China (Pinding, Zezhou,
Xiyang, Shouyang, and Taigu), where NTD prevalence is
among the highest in the world [48]. As described in
more detail in our previous report [48], NTD cases were
terminated fetuses affected by an NTD; controls were
terminated non-malformed fetuses. Information on ma-
ternal sociodemographic characteristics, lifestyle, and
folic acid supplementation was collected through
in-person interviews and by viewing medical records.
Maternal venous blood samples were collected at preg-
nancy termination. Fetal spinal cord and brain tissues
were collected by autopsy performed by experienced pa-
thologists. All samples were stored at − 80 °C until assay.
The study protocol was approved by the Institutional
Review Board of Peking University, and written in-
formed consent was obtained from all participating
women.
Experimental animals
ICR mice of 8–9 weeks old were used, as described pre-
viously [22]. Briefly, BaP (Sigma, USA) dissolved in corn
oil was intraperitoneally administered into pregnant
mice from E7 for four consecutive days (250–350 mg/
kg). Mice in the vitamin E co-exposure group were fed
with chow supplemented with the water-soluble
(±)-α-tocopherol succinate form of vitamin E (Sigma,
USA) beginning from E0.5 (0.125%, w/w) and treated
with BaP from E7 (250 mg/kg). On E10.5, embryos were
collected and carefully inspected for NTDs. All experi-
mental procedures were approved by the Institutional
Animal Care and Use Committee of Peking University
(certificate no. LA2013-36).
DNA methylation level analysis
DNA from neural tissues of human subjects was ex-
tracted with QIAamp DNA Mini Kit (QIAGEN, Hilden,
Germany) and E10.5 mouse DNA was extracted from
frozen neural tissues using TIANamp Genomic DNA Kit
(TIANGEN Biotech, Beijing, China). Then, 500 ng of
genomic DNA from each sample was bisulfite-treated
with EZ DNA methylation kit (Zymo Research, CA,
USA). The bisulfite conversion reaction was performed
in duplicate for each sample to minimize potential bias
caused by variable conversion efficiency, and pooled
bisulfite-treated DNA was used for subsequent analysis.
Human methylation study was performed in two phases.
In phase 1, Infinium HumanMethylation450 BeadChip
assay (450K, Illumina, San Diego, CA, USA) was used
for genomic methylation assay of bisulfite-treated DNA
from ten NTD cases and eight non-malformed controls,
which has been described in detail in our previous study
[23]. Methylation data of PAX3 gene was extracted from
the array data and used for validation in the next phase.
In phase 2, 73 NTD cases and 29 non-malformed con-
trol fetuses were included. The locations of the ampli-
cons to target the aberrant CpG regions are shown in
Fig. 1a. Bisulphite DNA was amplified by PCR and
primers for the PAX3 gene were designed using the on-
line tool Epidesigner (www.epidesigner.com). Primer se-
quences are listed in Additional file 5: Table S4. After
reverse transcription, fragmentation, and analysis on a
mass spectrometer (Sequenom, Inc., San Diego, USA),
EpiTYPER Analyzer software was used for translating
mass signal patterns into quantitative DNA methylation
levels of different CpG sites.
Methylation analysis of mouse neural tissues was
assayed with the same methods performed in phase 2 of
the human methylation study. The regions of gene se-
quence analyzed were the same as those in human PAX3
gene and three amplicons were designed, with two in
the promoter region and one in the body region, as
shown in Fig. 1b. See Additional file 6: Table S5 for PCR
primer sequences.
PAHs analysis
PAH concentrations in maternal blood were determined
with an Agilent 7890A-5975C gas chromatograph and
mass spectrometer equipped with a HP-5MS capillary
column (30 m × 0.25 mm × 0.25 μm), as described previ-
ously [24]. In the present study, 51 mother-fetus pairs
were available for PAH-methylation correlation analysis.
Oxidative stress assessment
The antioxidant capacity was determined by the reduced
ferric reducing antioxidant power (FRAP) assay accord-
ing to the manufacturer’s instructions (Beyotime Insti-
tute of Biotechnology, China) for determining the level
of TAC of mouse embryos. The TAC aims to measure
both small molecule and protein antioxidants, including
polyphenols, flavonoids, vitamins, and enzymes like
glutathione peroxidase and superoxide dismutase.
Briefly, neural tissues from E10.5 embryo samples were
homogenized in PBS. Freshly prepared FRAP reagent
was warmed to 37 °C before use. Then, 5 μl of the di-
luted sample was added to 180 μl of the FRAP reagent.
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The absorbance of the mixture was measured at 593 nm
using a Synergy 2 Multi-Mode Microplate Reader (Bio-
Tek, USA) after incubation for 4 min. The TAC of each
sample was calculated from the standard curve con-
structed using FeSO4 solution, and the results were
expressed as mmol/g protein, adjusted according to the
protein concentration of the samples. All samples were
loaded in duplicate. Protein concentration was deter-
mined using the BCA protein assay kit (Beyotime Insti-
tute of Biotechnology, China).
SOD activity was determined using the total super-
oxide dismutase assay kit with WST-8 (Beyotime Insti-
tute of Biotechnology, China). Briefly, 20 μl of sample
(E10.5 embryo samples were homogenized in lysis buf-
fer) was mixed with 160 μl of WST-8/enzyme working
solution. Then, 20 μl of reaction triggering working solu-
tion was added. After incubation at 37 °C for 30 min,
the absorbance was determined at 450 nm using a Syn-
ergy 2 Multi-Mode Microplate Reader (BioTek, USA).
The SOD activity was expressed as U/mg protein.
RNA isolation and real-time PCR
RNA was isolated from E10.5 embryos neural tissues
using Trizol (Invitrogen); genomic DNA was removed
by DNase I digestion (DNA-free, Ambion) and then
reverse-transcribed using random hexamers (Superscript
VILO cDNA synthesis kit). The abundance of mRNA of
Pax3 were analyzed using real-time PCR (iTaq™ Univer-
sal SYBR Green Supermix, BioRad) on a 7500 Fast Real
Time PCR system (Applied Biosystems), with each sam-
ple analyzed in triplicate. Primers are listed in Add-
itional file 7: Table S6. Relative quantification of gene
expression level was normalized according to the Gapdh
gene expression.
Whole mount in situ hybridization
Whole mount in situ hybridization on E9.5 control em-
bryos and embryos treated with BaP was performed ac-
cording to the procedures described by Yun et al. [49].
Pax3 probe was cloned by real-time PCR into pGEM-T
(Promega) and used to generate digoxygenin-labeled
cRNA probes by reverse transcription using T7 RNA
polymerase (Roche). For detection, anti-digoxigenin-AP
antibody (1:2000, Roche) in 1% sheep serum was used
and incubated overnight. Color detection was carried
out using NBT/BCIP developing solution (Roche) in
NTMT. After color development, embryos were imaged
with a DFC490 camera (Leica), and then embedded. Sec-
tions of 40 μm thickness were obtained using a
vibratome.
Statistical analyses
In the human subject study, differences in proportions
of population characteristics between NTD cases and
controls were examined with Pearson’s χ2 test. Inde-
pendent t test was performed to evaluate the difference
in methylation of CpGs between NTDs and controls in
phase 1, and adjusted for multiple testing with the
Benjamini-Hochberg false discovery rate (FDR) methods.
In phase 2, Shapiro-Wilk test was used to examine the
distribution of methylation values of NTD cases and
controls, and independent samples t test was used to
identify CpG sites that were differentially methylated be-
tween cases and controls. Odds ratio (OR) was calcu-
lated by logistic regression to evaluate the association
between higher methylation levels of PAX3 with the risk
of NTDs, adjusting for maternal education, occupation,
periconceptional folic acid use, fetal sex, and gestational
age. Correlation between differentially methylated CpG
sites in neural tissues and PAH concentrations in mater-
nal serum was analyzed with Spearman’s correlation ana-
lysis. In the mouse study, data on methylation level of
Pax3 gene, oxidative stress markers, and the abundance
of mRNA were presented as mean ± SE (SD). A one-way
analysis of variance (ANOVA) followed by LSD (equal
variances assumed) or Dunnett’s T3 (equal variances not
assumed) was used for testing the differences between
groups. A two-tail P value of < 0.05 was considered sta-
tistically significant. Statistical analyses were conducted
using SPSS 18.0.
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the HumanMethylation450 BeadChip assay. (DOCX 24 kb)
Additional file 3: Table S3. Correlation analysis of DNA methylation of
PAX3 in fetal neural tissues and PAH concentrations in maternal serum (N
= 51 mother-fetus pairs). (DOCX 22 kb)
Additional file 4: Figure S1. PAX3 methylation pattern assayed by
Sequenom EpiTYPER in NTD cases with and without folic acid
supplementation. (DOCX 148 kb)
Additional file 5: Table S4. The PCR primer sequences in Sequenom
EpiTYPER sequencing. (DOCX 15 kb)
Additional file 6: Table S5. The PCR primer sequences for mouse
methylation analysis. (DOCX 15 kb)
Additional file 7: Table S6. Sequences of primers for real-time PCR in
mouse study. (DOCX 15 kb)
Abbreviations
BaP: Benzo[a]pyrene; FDR: False discovery rate; FRAP: Ferric reducing
antioxidant power; HM450K: HumanMethylation450 BeadChip; NTDs: Neural
tube defects; PAH: Polycyclic aromatic hydrocarbon; ROS: Reactive oxygen
species; SOD: Superoxide dismutase; TAC: Total antioxidant capacity
Acknowledgements
Technical assistance from Kit-Yi Leung, Yanhui Xiao, and Wenli Ni is gratefully
acknowledged. All participants contributing to the original study subjects
recruit are acknowledged.
Lin et al. Clinical Epigenetics           (2019) 11:13 Page 11 of 13
Funding
This work was supported by the National Key Research and Development
Program, Ministry of Science and Technology, the Peoples’ Republic of China
(Grant No. 2016YFC1000501), and grants from the National Natural Science
Foundation of China (Grant No. 31371523 and 81773441), the Ministry of
Education of China (Grant No. 20130001110064), and the UK Medical
Research Council (N003713, K022741). NG is supported by Great Ormond
Street Hospital Children’s Charity and by the National Institute for Health
Research Biomedical Research Centre at Great Ormond Street Hospital for
Children NHS Foundation Trust and University College London.
Availability of data and materials
The data sets supporting the results of this article are included within the
article and its additional files.
Authors’ contributions
AR and LW conceived and designed the study. SL performed the
experiments, conducted data analyses, interpreted the data, and drafted the
manuscript. YH and CS helped with the experiments. AR, LW, CS, and NG
critically revised the paper. NG helped provide reagents, materials, and
experimental infrastructure. LJ and ZL contributed to human subject
recruitment. All authors read and approved the definitive version of the
manuscript.
Ethics approval and consent to participate
The study protocol was approved by the Institutional Review Board of
Peking University, and written informed consent was obtained from all
participating women. The animal experiments were approved by the
Institutional Animal Care and Use Committee of Peking University (certificate
no. LA2013-36).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute of Reproductive and Child Health, National Health Commission Key
Laboratory of Reproductive Health, and Department of Epidemiology and
Biostatistics, School of Public Health, Peking University Health Centre, Peking
University, Beijing 100191, China. 2Division of Birth Cohort Study, and
Department of Neonatal Surgery, Guangzhou Women and Children’s Medical
Centre, Guangzhou Medical University, Guangzhou, China. 3Developmental
Biology and Cancer Programme, UCL Great Ormond Street Institute of Child
Health, University College London, London WC1N 1EH, UK.
Received: 21 August 2018 Accepted: 8 January 2019
References
1. Mitchell LE. Epidemiology of neural tube defects. Am J Med Genet C Semin
Med Genet. 2005;135c(1):88–94.
2. Greene ND, Stanier P, Copp AJ. Genetics of human neural tube defects.
Hum Mol Genet. 2009;18(R2):R113–29.
3. Harris MJ, Juriloff DM. Mouse mutants with neural tube closure defects and
their role in understanding human neural tube defects. Birth Defects Res A
Clin Mol Teratol. 2007;79(3):187–210.
4. Wilde JJ, Petersen JR, Niswander L. Genetic, epigenetic, and environmental
contributions to neural tube closure. Annu Rev Genet. 2014;48:583–611.
5. Greene ND, Stanier P, Moore GE. The emerging role of epigenetic
mechanisms in the etiology of neural tube defects. Epigenetics. 2011;6(7):
875–83.
6. Weinhold B. Epigenetics: the science of change. Environ Health Perspect.
2006;114(3):A160–7.
7. Morgan HD, Santos F, Green K, Dean W, Reik W. Epigenetic reprogramming
in mammals. Hum Mol Genet. 2005;14 Spec No 1:R47–58.
8. Kim JK, Samaranayake M, Pradhan S. Epigenetic mechanisms in mammals.
Cell Mol Life Sci. 2009;66(4):596–612.
9. Wang L, Wang F, Guan J, Le J, Wu L, Zou J, et al. Relation between
hypomethylation of long interspersed nucleotide elements and risk of
neural tube defects. Am J Clin Nutr. 2010;91(5):1359–67.
10. Wu L, Wang L, Shangguan S, Chang S, Wang Z, Lu X, et al. Altered
methylation of IGF2 DMR0 is associated with neural tube defects. Mol Cell
Biochem. 2013;380(1–2):33–42.
11. Bai B, Zhang Q, Liu X, Miao C, Shangguan S, Bao Y, et al. Different
epigenetic alterations are associated with abnormal IGF2/Igf2 upregulation
in neural tube defects. PLoS One. 2014;9(11):e113308.
12. Liu Z, Wang Z, Li Y, Ouyang S, Chang H, Zhang T, et al. Association of genomic
instability, and the methylation status of imprinted genes and mismatch-repair
genes, with neural tube defects. Eur J Hum Genet. 2012;20(5):516–20.
13. Shangguan S, Wang L, Chang S, Lu X, Wang Z, Wu L, et al. DNA
methylation aberrations rather than polymorphisms of FZD3 gene increase
the risk of spina bifida in a high-risk region for neural tube defects. Birth
Defects Res A Clin Mol Teratol. 2015;103(1):37–44.
14. Tian T, Wang L, Shen Y, Zhang B, Finnell RH, Ren A. Hypomethylation of
GRHL3 gene is associated with the occurrence of neural tube defects.
Epigenomics. 2018;10(7):891–901.
15. Rochtus A, Izzi B, Vangeel E, Louwette S, Wittevrongel C, Lambrechts D, et
al. DNA methylation analysis of Homeobox genes implicates HOXB7
hypomethylation as risk factor for neural tube defects. Epigenetics. 2015;
10(1):92–101.
16. Phelan SA, Ito M, Loeken MR. Neural tube defects in embryos of diabetic
mice: role of the Pax-3 gene and apoptosis. Diabetes. 1997;46(7):1189–97.
17. Greene ND, Massa V, Copp AJ. Understanding the causes and prevention of
neural tube defects: insights from the splotch mouse model. Birth Defects
Res A Clin Mol Teratol. 2009;85(4):322–30.
18. Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N.
Review and update of mutations causing Waardenburg syndrome. Hum
Mutat. 2010;31(4):391–406.
19. Hol FA, Hamel BC, Geurds MP, Mullaart RA, Barr FG, Macina RA, et al. A
frameshift mutation in the gene for PAX3 in a girl with spina bifida and
mild signs of Waardenburg syndrome. J Med Genet. 1995;32(1):52–6.
20. Lu W, Zhu H, Wen S, Laurent C, Shaw GM, Lammer EJ, et al. Screening for
novel PAX3 polymorphisms and risks of spina bifida. Birth Defects Res A
Clin Mol Teratol. 2007;79(1):45–9.
21. Ren A, Qiu X, Jin L, Ma J, Li Z, Zhang L, et al. Association of selected
persistent organic pollutants in the placenta with the risk of neural tube
defects. Proc Natl Acad Sci U S A. 2011;108(31):12770–5.
22. Lin S, Ren A, Wang L, Huang Y, Wang Y, Wang C, et al. Oxidative stress and
apoptosis in benzo[a]pyrene-induced neural tube defects. Free Radic Biol
Med. 2018;116:149–58.
23. Wang L, Lin S, Zhang J, Tian T, Jin L, Ren A. Fetal DNA hypermethylation in
tight junction pathway is associated with neural tube defects: a genome-
wide DNA methylation analysis. Epigenetics. 2017;12(2):157–65.
24. Wang B, Jin L, Ren A, Yuan Y, Liu J, Li Z, et al. Levels of polycyclic aromatic
hydrocarbons in maternal serum and risk of neural tube defects in offspring.
Environ Sci Technol. 2015;49(1):588–96.
25. Fleming A, Copp AJ. Embryonic folate metabolism and mouse neural tube
defects. Science. 1998;280(5372):2107–9.
26. Fleming A, Copp AJ. A genetic risk factor for mouse neural tube defects:
defining the embryonic basis. Hum Mol Genet 2000;9(4):575–581.
27. Nye JS, Balkin N, Lucas H, Knepper PA, McLone DG, Charrow J.
Myelomeningocele and Waardenburg syndrome (type 3) in patients with
interstitial deletions of 2q35 and the PAX3 gene: possible digenic
inheritance of a neural tube defect. Am J Med Genet. 1998;75(4):401–8.
28. Agopian AJ, Bhalla AD, Boerwinkle E, Finnell RH, Grove ML, Hixson JE, et al.
Exon sequencing of PAX3 and T (brachyury) in cases with spina bifida. Birth
Defects Res A Clin Mol Teratol. 2013;97(9):597–601.
29. Wei D, Loeken MR. Increased DNA methyltransferase 3b (Dnmt3b)-mediated
CpG island methylation stimulated by oxidative stress inhibits expression of
a gene required for neural tube and neural crest development in diabetic
pregnancy. Diabetes. 2014;63(10):3512–22.
30. Zhong J, Xu C, Reece EA, Yang P. The green tea polyphenol EGCG alleviates
maternal diabetes-induced neural tube defects by inhibiting DNA
hypermethylation. Am J Obstet Gynecol. 2016;215(3):368. e1-.e10
31. Rochtus A, Winand R, Laenen G, Vangeel E, Izzi B, Wittevrongel C, et al.
Methylome analysis for spina bifida shows SOX18 hypomethylation as a risk
Lin et al. Clinical Epigenetics           (2019) 11:13 Page 12 of 13
factor with evidence for a complex (epi)genetic interplay to affect neural
tube development. Clin Epigenetics. 2016;8:108.
32. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls
imprinted expression of the Igf2 gene. Nature. 2000;405(6785):482–5.
33. Zhang X, Yazaki J, Sundaresan A, Cokus S, Chan SW, Chen H, et al. Genome-
wide high-resolution mapping and functional analysis of DNA methylation
in arabidopsis. Cell. 2006;126(6):1189–201.
34. Lev Maor G, Yearim A, Ast G. The alternative role of DNA methylation in
splicing regulation. Trends Genet. 2015;31(5):274–80.
35. Yearim A, Gelfman S, Shayevitch R, Melcer S, Glaich O, Mallm JP, et al. HP1
is involved in regulating the global impact of DNA methylation on
alternative splicing. Cell Rep. 2015;10(7):1122–34.
36. Tang WY, Levin L, Talaska G, Cheung YY, Herbstman J, Tang D, et al.
Maternal exposure to polycyclic aromatic hydrocarbons and 5’-CpG
methylation of interferon-gamma in cord white blood cells. Environ Health
Perspect. 2012;120(8):1195–200.
37. Herbstman JB, Tang D, Zhu D, Qu L, Sjodin A, Li Z, et al. Prenatal exposure
to polycyclic aromatic hydrocarbons, benzo[a]pyrene-DNA adducts, and
genomic DNA methylation in cord blood. Environ Health Perspect. 2012;
120(5):733–8.
38. Fang X, Dong W, Thornton C, Willett KL. Benzo[a]pyrene effects on glycine
N-methyltransferase mRNA expression and enzyme activity in Fundulus
heteroclitus embryos. Aquat Toxicol. 2010;98(2):130–8.
39. Sadikovic B, Rodenhiser DI. Benzopyrene exposure disrupts DNA
methylation and growth dynamics in breast cancer cells. Toxicol Appl
Pharmacol. 2006;216(3):458–68.
40. Dolinoy DC, Huang D, Jirtle RL. Maternal nutrient supplementation
counteracts bisphenol A-induced DNA hypomethylation in early
development. Proc Natl Acad Sci U S A. 2007;104(32):13056–61.
41. Bernal AJ, Dolinoy DC, Huang D, Skaar DA, Weinhouse C, Jirtle RL. Adaptive
radiation-induced epigenetic alterations mitigated by antioxidants. FASEB J.
2013;27(2):665–71.
42. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative stress,
DNA methylation and carcinogenesis. Cancer Lett. 2008;266(1):6–11.
43. Angelini F, Pagano F, Bordin A, Milan M, Chimenti I. The impact of
environmental factors in influencing epigenetics related to oxidative states
in the cardiovascular system. Oxid Med Cell Longev. 2017;2017:2712751.
44. Hitchler MJ, Domann FE. An epigenetic perspective on the free radical
theory of development. Free Radic Biol Med. 2007;43(7):1023–36.
45. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K. Free radical adducts
induce alterations in DNA cytosine methylation. Proc Natl Acad Sci U S A.
1994;91(4):1261–4.
46. Chia N, Wang L, Lu X, Senut MC, Brenner C, Ruden DM. Hypothesis:
environmental regulation of 5-hydroxymethylcytosine by oxidative stress.
Epigenetics. 2011;6(7):853–6.
47. Cyr AR, Hitchler MJ, Domann FE. Regulation of SOD2 in cancer by histone
modifications and CpG methylation: closing the loop between redox
biology and epigenetics. Antioxid Redox Signal. 2013;18(15):1946–55.
48. Liu J, Zhang L, Li Z, Jin L, Zhang Y, Ye R, et al. Prevalence and trend of
neural tube defects in five counties in Shanxi province of northern China,
2000 to 2014. Birth Defects Res A Clin Mol Teratol. 2016;106(4):267–74.
49. Pai YJ, Leung KY, Savery D, Hutchin T, Prunty H, Heales S, et al. Glycine
decarboxylase deficiency causes neural tube defects and features of non-
ketotic hyperglycinemia in mice. Nat Commun. 2015;6:6388.
Lin et al. Clinical Epigenetics           (2019) 11:13 Page 13 of 13
